Eversept Partners’s Replimune Group REPL Stock Holding History

Eversept Partners’s Portfolio REPL Stock Details REPL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$398K	Buy	+52,000	New	+$397K	0.02%	115

Other funds holding REPL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Eversept Partners's REPL Position: Q1 2026 in Review

Eversept Partners opened a new position in Replimune Group (REPL) in Q1 2026: 334,861 shares worth $2.56M. The stake represents 0.14% of the portfolio and ranks #82 among its holdings. This is a return to the name: Eversept Partners previously reported a position in REPL as recently as Q3 2025.

Eversept Partners first reported a position in REPL in Q3 2025 and has held it in 2 quarters since. 180 funds tracked by Wall St. Rank hold REPL as of Q1 2026.

Eversept Partners held 334,861 shares of Replimune Group worth $2.56M as of Q1 2026.
Replimune Group was a new Eversept Partners position in Q1 2026.
Replimune Group made up 0.14% of Eversept Partners's portfolio in Q1 2026, its #82 holding.
Eversept Partners first reported a position in Replimune Group in Q3 2025 and has held it in 2 quarters since.
180 funds tracked by Wall St. Rank held Replimune Group as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.